[{"orgOrder":0,"company":"St. Jude Children","sponsor":"CURE Childhood Cancer, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Oncology","graph2":"Phase I","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Jude Children \/ CURE Childhood Cancer, Inc.","highestDevelopmentStatusID":"6","companyTruncated":"St. Jude Children \/ CURE Childhood Cancer, Inc."},{"orgOrder":0,"company":"Institute for Clinical and Experimental Medicine","sponsor":"Charite University, Berlin, Germany | Miltenyi Biomedicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CZECH REPUBLIC","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Immunology","graph2":"Undisclosed","graph3":"Institute for Clinical and Experimental Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute for Clinical and Experimental Medicine \/ Charite University, Berlin, Germany | Miltenyi Biomedicine","highestDevelopmentStatusID":"1","companyTruncated":"Institute for Clinical and Experimental Medicine \/ Charite University, Berlin, Germany | Miltenyi Biomedicine"},{"orgOrder":0,"company":"Shanghai Zhangjiang Biotechnology Limited Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"Shanghai Zhangjiang Biotechnology Limited Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Zhangjiang Biotechnology Limited Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Zhangjiang Biotechnology Limited Company \/ Undisclosed"},{"orgOrder":0,"company":"University of Ulm","sponsor":"Technical University of Munich | WiSP Wissenschaftlicher Service Pharma GmbH | German CLL Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"University of Ulm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Ulm \/ Technical University of Munich | WiSP Wissenschaftlicher Service Pharma GmbH | German CLL Study Group","highestDevelopmentStatusID":"8","companyTruncated":"University of Ulm \/ Technical University of Munich | WiSP Wissenschaftlicher Service Pharma GmbH | German CLL Study Group"},{"orgOrder":0,"company":"University Hospital Muenster","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Neurology","graph2":"Phase IV","graph3":"University Hospital Muenster","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University Hospital Muenster \/ Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital Muenster \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Neurology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Neurology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"University of Oxford","sponsor":"National Health Service, UK | Pfizer Inc | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ National Health Service, UK | Pfizer Inc | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"9","companyTruncated":"University of Oxford \/ National Health Service, UK | Pfizer Inc | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"University of Chicago","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Neurology","graph2":"Phase IV","graph3":"University of Chicago","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Chicago \/ Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"University of Chicago \/ Sanofi"},{"orgOrder":0,"company":"Northwestern University","sponsor":"GSK | National Comprehensive Cancer Network","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwestern University \/ GSK | National Comprehensive Cancer Network","highestDevelopmentStatusID":"8","companyTruncated":"Northwestern University \/ GSK | National Comprehensive Cancer Network"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Neurology","graph2":"Phase III","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of British Columbia \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"University of British Columbia \/ Sanofi"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Neurology","graph2":"Phase IV","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johns Hopkins University \/ Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"Johns Hopkins University \/ Sanofi"},{"orgOrder":0,"company":"Boston Children's Hospital","sponsor":"Dana-Farber Cancer Institute | Children's Hospital Medical Center, Cincinnati | Children's Hospital Los Angeles | Fred Hutch\/University of Washington\/Seattle Children's Cancer Consortium | Baylor College of Medicine | Children's Hospital of Philadelphia |","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Boston Children's Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Children's Hospital \/ Dana-Farber Cancer Institute | Children's Hospital Medical Center, Cincinnati | Children's Hospital Los Angeles | Fred Hutch\/University of Washington\/Seattle Children's Cancer Consortium | Baylor College of Medicine | Children's Hospital of Philadelphia |","highestDevelopmentStatusID":"8","companyTruncated":"Boston Children's Hospital \/ Dana-Farber Cancer Institute | Children's Hospital Medical Center, Cincinnati | Children's Hospital Los Angeles | Fred Hutch\/University of Washington\/Seattle Children's Cancer Consortium | Baylor College of Medicine | Children's Hospital of Philadelphia |"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"Central Texas Neurology Consultants","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Neurology","graph2":"Phase III","graph3":"Central Texas Neurology Consultants","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Central Texas Neurology Consultants \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Central Texas Neurology Consultants \/ Sanofi"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hackensack Meridian Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hackensack Meridian Health \/ Undisclosed"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Neurology","graph2":"Phase IV","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"UT Southwestern Medical Center \/ Sanofi"},{"orgOrder":0,"company":"Seah Lim M.D.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"CAMPATH-1 antigen","graph1":"Neurology","graph2":"Phase II","graph3":"Seah Lim M.D.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seah Lim M.D. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seah Lim M.D. \/ Undisclosed"},{"orgOrder":0,"company":"Cellectis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"||CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ Undisclosed"},{"orgOrder":0,"company":"Cellectis","sponsor":"EIB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2024","type":"Financing","leadProduct":"Alemtuzumab","moa":"||CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectis \/ EIB","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ EIB"},{"orgOrder":0,"company":"Cellectis","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2023","type":"Agreement","leadProduct":"Alemtuzumab","moa":"||CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectis \/ European Investment Bank","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ European Investment Bank"},{"orgOrder":0,"company":"Cellectis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"||CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Cellectis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2021","type":"Partnership","leadProduct":"Alemtuzumab","moa":"||CD22","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Cellectis","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Cellectis"}]

Find Clinical Drug Pipeline Developments & Deals for Alemtuzumab

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : UCART22,Alemtuzumab

                          Therapeutic Area : Oncology

                          Study Phase : Phase I

                          Sponsor : Cellectis

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          Details : In Cellectis sponsored trials, alemtuzumab is currently used as part of the lymphodepleting regimen for UCART22 in the BALLI-01 clinical trial in relapsed/refractory ALL, and for UCART123 in the AMELI-01 clinical trial in relapsed/refractory AML, but not...

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          May 11, 2021

                          Lead Product(s) : UCART22,Alemtuzumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Cellectis

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          Sanofi Company Banner

                          02

                          Lead Product(s) : Alemtuzumab

                          Therapeutic Area : Neurology

                          Study Phase : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Alemtuzumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Multiple Sclerosis.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          December 11, 2017

                          Lead Product(s) : Alemtuzumab

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          03

                          Lead Product(s) : Alemtuzumab

                          Therapeutic Area : Neurology

                          Study Phase : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Alemtuzumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Multiple Sclerosis, Relapsing-Remitting.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          October 02, 2014

                          Lead Product(s) : Alemtuzumab

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          04

                          Lead Product(s) : Alemtuzumab

                          Therapeutic Area : Neurology

                          Study Phase : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Alemtuzumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Multiple Sclerosis, Relapsing-Remitting.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          July 31, 2014

                          Lead Product(s) : Alemtuzumab

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          05

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : The Company plans to use the proceeds of Tranche C towards the development of its pipeline of allogeneic CAR T-cell product candidates: UCART22 and UCART20x22.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          December 10, 2024

                          Lead Product(s) : UCART22,Alemtuzumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : EIB

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank

                          06

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : UCART22 is an allogeneic, off-the-shelf gene-edited T-cell product candidates designed for the treatment of R/R B-ALL, in combination with alemtuzumab.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          August 01, 2024

                          Lead Product(s) : UCART22,Alemtuzumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : UCART22 is one of Cellectis’ wholly owned, allogeneic, off-the-shelf gene-edited T-cell product candidates designed for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          April 24, 2023

                          Lead Product(s) : UCART22,Alemtuzumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : The Company plans to use the proceeds towards the development of its pipeline of allogeneic CAR T-cell product candidates: UCART22, UCART20x22, UCART123 and UCARTCS1.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          April 04, 2023

                          Lead Product(s) : UCART22,Alemtuzumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : European Investment Bank

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          09

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Alemtuzumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Multiple Sclerosis.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          May 01, 2017

                          Lead Product(s) : Alemtuzumab

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase IV

                          Sponsor : Sanofi

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Institute for Clinical and Experimental Medicine

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Institute for Clinical and Experimental Medicine

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : MabCampath is a Antibody drug candidate, which is currently being evaluated in clinical studies for the treatment of Kidney Transplantation.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          March 17, 2016

                          Lead Product(s) : Alemtuzumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Undisclosed

                          Sponsor : Charite University, Berlin, Germany | Miltenyi Biomedicine

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank